Open AccessMetabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study
Author(s) -
Praveen Rikhari,
Ashutosh Kumar,
Prabhat Agrawal,
Himanshu Kumar
Publication year - 2022
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_2161_21
Subject(s) - olanzapine , risperidone , medicine , metabolic syndrome , waist , schizophrenia (object oriented programming) , diabetes mellitus , dopamine antagonist , prospective cohort study , body mass index , endocrinology , antipsychotic , psychiatry , haloperidol , dopamine
Schizophrenia spectrum and other psychotic disorders are common disorders often requiring long-term treatment with atypical antipsychotics, which might cause metabolic dysfunctions. We aimed to study the metabolic dysfunctions with olanzapine and risperidone in patients with schizophrenia spectrum and other psychotic disorders. We also explored the incidence of new-onset metabolic syndrome and its predictors.